CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 11 enrolled
Drug / intervention
ABT-450 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01221298
NCT01221298Phase 2Completed
CompareCT.gov

An Open-Label Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV) in Treatment-Naive Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

AbbVie (prior sponsor, Abbott)·interventional·Posted Oct 15, 2010·Updated Jan 8, 2015

In Brief

A Phase 2 clinical trial evaluating ABT-450, ABT-072, and 2 other interventions for Hepatitis C and 3 related conditions. Completed, enrolled 11 participants across 4 sites.

Detailed Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of ABT-450 with ritonavir (ABT-450/r) dosed in combination with ABT-072 and ribavirin (RBV) in treatment-naïve participants with genotype 1 chronic hepatitis C virus (HCV) infection.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C, HCV, Chronic Hepatitis C Infection, Hepatitis C Genotype 1
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedOct 15, 2010
Enrollment StartOct 1, 2010
Primary CompletionMay 1, 2011
Study CompletionApr 1, 2012
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 15.7 years ago

Interventions

ABT-450drug

tablets

ABT-072drug

tablets

Ribavirindrug

tablets

Ritonavirdrug

capsules